Kunny C Dans1, Sarah R Freeman1, Tiezhu Lin1,2, Amit Meshi1,3,4, Sergio Olivas1, Lingyun Cheng1, Manuel J Amador-Patarroyo1,5, William R Freeman6. 1. Department of Ophthalmology, Jacobs Retina Center at the Shiley Eye Institute, University of California San Diego, 9415 Campus Point Drive, La Jolla, CA, 92037, USA. 2. Department of Ophthalmology, He Eye Hospital, He University, Shenyang, China. 3. Department of Ophthalmology, Rabin Medical Center, Petah Tikva, Israel. 4. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 5. Department of Ophthalmology, Escuela Superior de Oftalmologia, Instituto Barraquer de America, Bogota, Colombia. 6. Department of Ophthalmology, Jacobs Retina Center at the Shiley Eye Institute, University of California San Diego, 9415 Campus Point Drive, La Jolla, CA, 92037, USA. wrfreeman@ucsd.edu.
Abstract
PURPOSE: To determine the proportion of treatment-experienced eyes with exudative age-related macular degeneration successfully treated with every-4-week aflibercept that can be kept dry on fixed every-8-week aflibercept injections (maintenance). METHODS: In this retrospective chart review, we evaluated our cohort of patients treated with a treatment paradigm for CNV in AMD. Initially, patients were treated with bevacizumab or ranibizumab and switched to every-4-week aflibercept when therapeutic responses were not durable or were suboptimal. Maintenance every-8-week therapy was initiated when the retina was completely dry on every-4-week aflibercept therapy. The primary outcome measure was recurrence of exudation on optical coherence tomography (OCT) during maintenance. RESULTS: Thirty-six eyes of 31 consecutive patients with median age of 79 years (range, 65-89) were included. Maintenance was started after a median of 34 (range, 8-88) injections. Recurrence was observed in 20 eyes (55%). Of these, 11 eyes (31%) reactivated at 8 weeks. Median time to failure of maintenance schedule was 40 weeks by Kaplan-Meier analysis. Baseline demographic and anatomic characteristics were not associated with failure of maintenance schedule. CONCLUSION: In treatment-experienced eyes that respond completely to every-4-week aflibercept, maintenance therapy with every-8-week injections can only temporarily maintain anatomic success with the majority of eyes developing recurring activity. This regimen fails early in one third of eyes and has a median effective duration of 40 weeks. Aflibercept appears to be inadequate to maintain control of exudation in most eyes in at least half of eyes undergoing long-term therapy.
PURPOSE: To determine the proportion of treatment-experienced eyes with exudative age-related macular degeneration successfully treated with every-4-week aflibercept that can be kept dry on fixed every-8-week aflibercept injections (maintenance). METHODS: In this retrospective chart review, we evaluated our cohort of patients treated with a treatment paradigm for CNV in AMD. Initially, patients were treated with bevacizumab or ranibizumab and switched to every-4-week aflibercept when therapeutic responses were not durable or were suboptimal. Maintenance every-8-week therapy was initiated when the retina was completely dry on every-4-week aflibercept therapy. The primary outcome measure was recurrence of exudation on optical coherence tomography (OCT) during maintenance. RESULTS: Thirty-six eyes of 31 consecutive patients with median age of 79 years (range, 65-89) were included. Maintenance was started after a median of 34 (range, 8-88) injections. Recurrence was observed in 20 eyes (55%). Of these, 11 eyes (31%) reactivated at 8 weeks. Median time to failure of maintenance schedule was 40 weeks by Kaplan-Meier analysis. Baseline demographic and anatomic characteristics were not associated with failure of maintenance schedule. CONCLUSION: In treatment-experienced eyes that respond completely to every-4-week aflibercept, maintenance therapy with every-8-week injections can only temporarily maintain anatomic success with the majority of eyes developing recurring activity. This regimen fails early in one third of eyes and has a median effective duration of 40 weeks. Aflibercept appears to be inadequate to maintain control of exudation in most eyes in at least half of eyes undergoing long-term therapy.
Authors: Ilkay Kilic Muftuoglu; Cheryl A Arcinue; Frank F Tsai; Mostafa Alam; Raouf Gaber; Natalia Camacho; Qisheng You; William R Freeman Journal: Am J Ophthalmol Date: 2016-04-02 Impact factor: 5.258
Authors: Daniel F Martin; Maureen G Maguire; Stuart L Fine; Gui-shuang Ying; Glenn J Jaffe; Juan E Grunwald; Cynthia Toth; Maryann Redford; Frederick L Ferris Journal: Ophthalmology Date: 2012-05-01 Impact factor: 12.079
Authors: Cheryl A Arcinue; Feiyan Ma; Giulio Barteselli; Lucie Sharpsten; Maria Laura Gomez; William R Freeman Journal: Am J Ophthalmol Date: 2014-11-18 Impact factor: 5.258
Authors: Usha Chakravarthy; Simon P Harding; Chris A Rogers; Susan M Downes; Andrew J Lotery; Lucy A Culliford; Barnaby C Reeves Journal: Lancet Date: 2013-07-19 Impact factor: 79.321
Authors: Allen C Ho; Brandon G Busbee; Carl D Regillo; Mark R Wieland; Sherri A Van Everen; Zhengrong Li; Roman G Rubio; Phillip Lai Journal: Ophthalmology Date: 2014-07-09 Impact factor: 12.079
Authors: Jeffrey S Heier; David M Brown; Victor Chong; Jean-Francois Korobelnik; Peter K Kaiser; Quan Dong Nguyen; Bernd Kirchhof; Allen Ho; Yuichiro Ogura; George D Yancopoulos; Neil Stahl; Robert Vitti; Alyson J Berliner; Yuhwen Soo; Majid Anderesi; Georg Groetzbach; Bernd Sommerauer; Rupert Sandbrink; Christian Simader; Ursula Schmidt-Erfurth Journal: Ophthalmology Date: 2012-10-17 Impact factor: 12.079